Login to Your Account

Metabasis Gets $10M Up Front in Roche HepDirect Collaboration

By Trista Morrison

Monday, August 11, 2008
Metabasis Therapeutics Inc. signed a $203 million research collaboration with F. Hoffmann La-Roche Ltd., resulting in some much-needed validation for its HepDirect liver-targeting technology as well as a boost to its stock price and cash balance. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription